TY - JOUR
T1 - Serum krebs von den lungen-6 for predicting the severity of COVID-19 lung injury
T2 - A systematic review and meta-analysis
AU - Witarto, Andro Pramana
AU - Witarto, Bendix Samarta
AU - Putra, Achmad Januar Er
AU - Pramudito, Shidi Laras
AU - Rosyid, Alfian Nur
N1 - Publisher Copyright:
© 2021, Pasteur Institute of Iran. All rights reserved.
PY - 2021/10
Y1 - 2021/10
N2 - Introduction: Lung injury is common in COVID-19 patients. The severity of lung injury appears to be reflected in serum KL-6, a glycoprotein expressed on type II alveolar epithelium. This study aims to assess the role of serum KL-6 in reflecting the severity of lung injury in COVID-19 patients. Methods: A systematic search was conducted in Scopus, PubMed, Wiley Online Library, and ProQuest. Articles were screened based on several eligibility criteria and assessed for study quality using NOS. Results: This systematic review included four studies involving a total of 151 adult COVID-19 patients. Pooled analysis revealed that serum KL-6 was significantly higher in severe patients (SMD = 1.16; 95% CI = 0.69–1.63) with moderately high pooled sensitivity (79%; 95% CI = 61–91%) and specificity (86%; 95% CI = 72–95%). Conclusion: High serum KL-6 may depict more severe lung injury in COVID-19 patients with moderately high sensitivity and specificity.
AB - Introduction: Lung injury is common in COVID-19 patients. The severity of lung injury appears to be reflected in serum KL-6, a glycoprotein expressed on type II alveolar epithelium. This study aims to assess the role of serum KL-6 in reflecting the severity of lung injury in COVID-19 patients. Methods: A systematic search was conducted in Scopus, PubMed, Wiley Online Library, and ProQuest. Articles were screened based on several eligibility criteria and assessed for study quality using NOS. Results: This systematic review included four studies involving a total of 151 adult COVID-19 patients. Pooled analysis revealed that serum KL-6 was significantly higher in severe patients (SMD = 1.16; 95% CI = 0.69–1.63) with moderately high pooled sensitivity (79%; 95% CI = 61–91%) and specificity (86%; 95% CI = 72–95%). Conclusion: High serum KL-6 may depict more severe lung injury in COVID-19 patients with moderately high sensitivity and specificity.
KW - Biomarker
KW - COVID-19
KW - Infectious disease
KW - Krebs von den Lungen-6
KW - Lung injury
UR - http://www.scopus.com/inward/record.url?scp=85121114442&partnerID=8YFLogxK
U2 - 10.52547/IBJ.25.6.381
DO - 10.52547/IBJ.25.6.381
M3 - Review article
AN - SCOPUS:85121114442
SN - 1028-852X
VL - 25
SP - 381
EP - 389
JO - Iranian Biomedical Journal
JF - Iranian Biomedical Journal
IS - 6
ER -
